

Sunday 16 October: EDUCATION DAY

0800-1900		Registration				Foyer Level 2
0900-1030	<p>Auditorium</p> <p>HSANZ <i>Lymphomas in Unusual Sites</i> Chair: David Joske Graham Young: The Spectrum of Extranodal non-Hodgkin's Lymphoma [1] Pier Luigi Zinzani (sponsored by Amgen): Non-gastrointestinal MALT Lymphomas [2] Peter O'Brien: Primary CNS Lymphoma [3]</p>	<p>Harbourside Room</p> <p>ANZSBT <i>Immunohaematology</i> Chair: Anne Fletcher Jill Storry: Molecular Basis and Investigation of Blood Group Genes [4] Steve Henry: KODE™CAE: Creating the World's First ABO Analytical Control System [5]</p>	<p>Harbourside Mtg Room 3</p> <p>ASTH <i>Cardiovascular Risk</i> Chair: Chris Ward Jean-Marie Freyssinet: Microparticles as Pathogenic Markers of Atherothrombotic Risk [6] Kenneth Clemetson: Serotonin and Cardiovascular Disease: A Platelet Connection? [7] Geoffrey Tofler: Haemostatic Risk Factors for Cardiovascular Disease [8]</p>	<p>Harbourside Mtg Room 2</p> <p>BMTSAA <i>Plenary Session</i> Chair: Annette Trickett Ian Nivison-Smith: Stem Cell Transplantation in Australia and New Zealand: Overview and Current Trends [9] Marcus Vowels: Current Issues with Cord Blood Banking and Transplantation [10] David Gottlieb: Cellular Immunotherapy for Treatment of Opportunistic Infections in Immunocompromised Bone Marrow Transplant Recipients [11]</p>	<p>Harbourside Mtg Room 4</p> <p>NURSES Chair: Angela Booth Liz Pirie: Competency Assessment for Blood Transfusion Practice [12] Dawn Thorp: The Evolution of Haematology Nursing [13] Rosita van Kuilenburg: Development of the Haematology Nurse Practitioner [14]</p>	
1030-1100	Morning Tea				Foyer Level 2	
1100-1230	<p>Auditorium</p> <p>HSANZ / BMTSAA <i>Stem Cell Transplantation</i> Chair: Jeff Szer Alois Gratwohl: Blood or Marrow for Haematopoietic Stem Cell Transplantation [15] Peter Bardy: Donor Selection – Molecular Considerations [16] Anthony Schwarzer: The Importance or Otherwise of Cellular Assays, NK cells and Killer Immunoglobulin-Like Receptors as an Adjunct to Allogeneic Hematopoietic Stem Cell (HSC) Donor Selection [17]</p>	<p>Harbourside Room</p> <p>ANZSBT <i>Transfusion Transmitted Infection</i> Chair: Tony Keller Roger Dodd: Emerging Infections: WNV and Beyond [18] Kit Lin (sponsored by CSL Bioplasma): Lessons Learnt from the SARS Epidemic [19]</p>	<p>Harbourside Mtg Room 3</p> <p>ASTH <i>Bleeding Disorders</i> Chair: Mark Smith Peter George: Molecular Diagnosis of Haemophilia [20] Boyd Webster: Inherited Platelet Disorders [21]</p>	<p>Auditorium</p> <p>BMTSAA <i>Combined session with HSANZ</i></p>	<p>Harbourside Mtg Room 4</p> <p>NURSES Chair: Fiona Jolly David Joske: Complementary Medicine Therapies in a Teaching Hospital [22] Tracy King: Myeloma - Novel Therapies and Future Directions [23] Georgia Lidstone & Maureen O'Brien: Haplo-identical Transplants - The Alfred Experience [24]</p>	
1230-1330	<p>PLENARY: BARRY FIRKIN ORATION Chair: Hatem Salem Peter Castaldi: The Man and His Legacy [25]</p>				Auditorium	

1330-1430	Lunch ASTH AGM BMTSAA AGM			Foyer Level 2 Harbourside Meeting Room 3 Harbourside Meeting Room 2
1430-1600	Auditorium HSANZ (Joint session with NURSES) Fertility Issues for the Haematology Patient Chair: Philip Campbell Ann Conway: Male Fertility: Effects of Chemoradiotherapy and Strategies for Preservation [26] Peter Illingworth: Female Fertility: Effects of Chemoradiotherapy and Strategies for Preservation [27] Michael Friedlander: Pregnancy During and After Chemoradiotherapy [28]	Harbourside Room ANZSBT / ASTH Joint Symposium Bloody Problems Chair: Alessandra Bianchi Lynn Boshkov: Pre-emptive Management of Challenging Surgical and Critical Bleeding Scenarios [29] Kerry Gunn: Attempting to Apply Logic to Chaos in Perioperative Bleeding: An Anaesthetist's Viewpoint [30]	Harbourside Mtg Room 2 BMTSAA Free Communications 1 Chair: Gail Lazzaro Annabella Chang: Influence of Diluent Composition on Membrane Integrity of Thawed CD34+ Cells [31] Jessica Stylianou: Optimal Storage Time and Temperature of Unprocessed Cord Blood [32] Devendra Hiwase: Peripheral Blood Stem Cell Collection: Evaluation of Factors that may Affect Collection Efficiency (CE) of Machine [33] Christine Hicks: Viable CD133+/CD34+ and CD34+ Stem Cell Subsets in Prediction of Haematopoietic Engraftment in Multiple Myeloma Patients Undergoing Autologous Peripheral Blood Stem Cell Transplantation [34] Open Forum – Current Issues	Auditorium NURSES Combined session with HSANZ
1600-1630	Afternoon Tea			Foyer, Level 2
1630-1730	Auditorium HSANZ Myeloproliferative Disorders Chair: Peter Browett Ayalew Tefferi: Classification, Pathogenesis, Diagnosis and Treatment Advances [35] Timothy Hughes: Current Status and Future of ABL Kinase Inhibitors for CML [36]	Harbourside Room ANZSBT/ASTH Joint Symposium (contd) Bloody Problems Chair: James Isbister Shannon Farmer: Your Body, Your Choice [37] Axel Hofmann: Cost Effectiveness of Transfusion Therapy vs. Blood Conservation Therapies [38]	Harbourside Mtg Room 2 BMTSAA Free Communications 2 Chair: Dianne Tucker Lijun Bai: A SYBR Green - Based Real Time PCR Method for Detection of Haemopoietic Chimerism in Allogenic Stem Cell Transplant Recipients [39] John Moore: Improved Disease Survival Without Increased GVHD Using Low Dose Cyclosporine and Prednisone in Allogenic Stem Cell Transplantation. A Case Control Study [40] Melina Webb: Filtration of Haemopoietic Progenitor Cell Products at the Time of Infusion Does Not Reduce Recovery of Total Nucleated or Viable CD34+ Cells [41]	Harbourside Mtg Room 4 NURSES Chair: Rosita Van Kuilenburg Alois Gratwohl: Emerging Trends in BMT -- the European Experience [42]
1730-1930	Welcome Reception in Exhibition Area Sponsored by Amgen			Bayside Banquet Hall – Ground Floor

Monday 17 October

0800-1800	Registration			Foyer Level 2
0830-1000	<p>HSANZ Free Communications:</p> <p>1 Lymphoma / HD (Auditorium) Chair: Michael Harvey Abs # 43 – 48</p> <p>2 Myeloma Biology (Mtg Room 2) Chair: Bik To Abs # 49 – 54</p> <p>3 Transplantation / Cell Therapy (Mtg Room 5) Chair: Jeff Szer Abs # 55 – 60</p> <p>Session sponsored by Pharmaco</p> <p>4 Leukaemia Biology (Skyline Room 1) Chair: Ken Bradstock Abs # 61 – 66</p>	<p>Harbourside Room</p> <p>ANZSBT Presidential Symposium Chair: Ken Davis Darryl Maher: Removal of Infective Prions by the Chromatographic Processes of Plasma-derived Albumin and Immunoglobulin [67] Jennifer Curnow: Increased Red Cell Susceptibility to Apoptotic Change is Associated with Duration of Packed Cell Storage [68] Richard Charlewood: Cryoprecipitate Audit Within Six Centres in New Zealand [69] Kristen Glenister: Identification of Proteins that Accumulate in the Supernatant of Platelet Concentrates During Storage [70] Angela Anniss: Storage Related Increase in Red Blood Cell (RBC) Adhesion to Vascular Endothelium: Effects of Bacterial and Inflammatory Activation [71]</p>	<p>Harbourside Mtg Room 3</p> <p>ASTH Free Communications 1 Clinical Challenges Chair: Emma Perrin & Paul Harper Jake Shortt: Autologous Stem Cell Transplantation for Plasmablastic Lymphoma in a Patient With Severe Haemophilia A [72] Paul Harper: The d-dimer Concentration Increases with Age Causing a Marked Effect on the d-dimer Assay Specificity [73] Linda Saravanan: Afibrinogenaemia Due to a Compound Heterozygosity for Two Termination Events in the Aα Chain [74] Joyce Low: Hypo/dysfibrinogenaemia Associated with Haemorrhage, Thrombosis and Pulmonary Hypertension [75] Luke Bereznicki: The Use of Thromboprophylaxis for Venous Thromboembolism (VTE) in Hospitalised Medical Patients [76] Emma Perrin: A Comparison of Enoxaparin and Unfractionated Heparin in Combination with Tirofiban During Percutaneous Coronary Intervention: Effects on Inhibition of Coagulation and Activation of Platelets [77]</p>	<p>Harbourside Mtg Room 4</p> <p>NURSES Free Communications 1: Apheresis Chair: Christine Akers Tamla Tait: The Impact of Refractory Thrombotic Thrombocytopenia Purpura (TTP) on an Apheresis Unit and Resources - A Case Study [78] Claire Dowsing: Assessing and Maintaining Apheresis Competency in the Therapeutic Setting [79] Katherine Stephen: Successful Mobilisation and PBSC Harvest of Stem Cells following AMD3100 in 4 Paediatric Patients: The Children's Hospital at Westmead's Experience [80] Barbara O'Callaghan: Daily Granulocyte Colony Stimulating Factor (G-csf) Versus Twice-Daily G-csf Administration in Mobilisation of Peripheral Blood Stem Cells in Healthy Donors [81] Clair Scott: Low Density Lipoprotein (LDL) Apheresis: A Case Report using LDL Apheresis in Treatment for Familial Hypercholesterolaemia [82]</p>
1000-1100	<p>Auditorium</p> <p>HSANZ / BMTSANZ Symposium Stem Cell Biology Chair: John Rasko Margaret Goodell: Haematopoietic Stem Cells [83] Paul Simmons: Prospective Isolation of Mesenchymal Stem Cells in Man and Mouse [84]</p>	<p>Harbourside Room</p> <p>ANZSBT Transfusion Related Acute Lung Injury (TRALI) Chair: Ken Nollett Lynn Boshkov: TRALI: What Do We Know and What Can We Do About It? [85]</p>	<p>Harbourside Mtg Room 3</p> <p>ASTH Symposium Coagulation and Inflammation Chair: Hatem Salem Jean-Marie Freyssinet: Membrane Microparticles in Pathophysiology [86] Chris Jackson: Protein C, Inflammation and Wound Healing [87]</p>	<p>Harbourside Mtg Room 4</p> <p>NURSES Chair: Mary McGurgan Catherine McGrath: Transplant Experience of Lymphoma Patients and Their Carers [88] Moirra Stephens: Fatigue Management in Haematology Patients [89]</p>
1100-1130	Morning Tea			Exhibition Area - Bayside Banquet Hall – Ground Floor
1130-1230	<p>PLENARY CARL DE GRUCHY ORATION Chair: Mark Hertzberg James Wiley: A Haematological Voyage Round My Mentors and Colleagues [90]</p>			Auditorium
1230-1330	<p>Lunch AGM for HSANZ Apheresis Interest Group Meeting</p>			Exhibition Area - Bayside Banquet Hall – Ground Floor Auditorium Harbourside Meeting Room 4

1330-1500	<p>Auditorium</p> <p>HSANZ & ASTH Presidential Symposium Chairs: Mark Hertzberg & Hatem Salem Kirsten Herbert: G-CSF and an RARα Specific Agonist, VTP195183, Synergize to Enhance the Mobilization of Haematopoietic Stem and Progenitor Cells [91] Vivien Chen: Tissue Factor Activation Involves Disulfide Switching [92] Jason Kovacic: Effects of Stem-Cell Mobilization with Recombinant Human Granulocyte-Colony Stimulating Factor in Patients with Chronic Refractory Ischemic Heart Disease [93] Helena Liang: A Common Ancestral Glycoprotein (GP) IX Gene Mutation (Asn45Ser) Causes Bernard-Soulier Syndrome (BSS) in European Families from Northern Europe and Australia [94] Andrew Perkins: A Global Role for EKLF in Definitive and Primitive Erythropoiesis [95] Andrew Wei: Epstein Barr Virus Encodes a Bcl-2 Homologue (BHRF-1) that Causes Chemoresistance by a Novel Mechanism Immune From Mammalian Regulation [96]</p>	<p>Harbourside Room</p> <p>ANZSBT Symposium Practising Smarter Chair: Kathryn Robinson Sandra Gray: Lessons Learnt from Scotland [97] Kit Lin (sponsored by CSL Bioplasma): The Hong Kong Experience [98] Ross Wilson: What Could Australia's Model System Look Like? [99]</p>	<p>Harbourside Mtg Room 4</p> <p>NURSES Free Communications 2: Clinical Chair: Yvonne Gonet Catherine Wood: Female Genital Graft Versus Host Disease: A Case Study [100] Penny McCarthy: Haemophilia Care For Nurses in Non-Specialist Centres [101] Julija Sipavicius: Development of a Tool to Measure the Acuity of Haematology and Stem Cell Transplant Patients [102] Cassandra Reid: Outpatient Based Bone Marrow Transplantation: The Royal North Shore Experience [103] Beverleigh Quested: A Collaborative Project to Improve Platelet Ordering and Administration [104] Karen O'Shea: A Transfusion Reaction with a Tingle [105]</p>	
1500-1530	Exhibition Area - Bayside Banquet Hall – Ground Floor			
1530-1630	<p>Auditorium</p> <p>HSANZ Symposium Factors Influencing Outcome in CLL Chair: Stephen Mulligan Thomas Kipps: Immunoglobulin Mutations and ZAP70 in CLL [106] Michael Keating (sponsored by Roche): Surviving with CLL in 2005 [107]</p>	<p>Harbourside Room</p> <p>ANZSBT Free Communications 1: Transfusion Practice Improvement Chair: Nicole Staples Abs # 108 – 111</p> <p>Session sponsored by Novo Nordisk</p>	<p>Harbourside Mtg Room 3</p> <p>ASTH Symposium Targeting the Platelet Chair: Marie-Christine Morel-Kopp Kenneth Clemetson: New Antiplatelet Agents [112] Robert Andrews: Molecular Targets of Platelet Activation [113]</p>	<p>Harbourside Mtg Room 4</p> <p>NURSES Chair: Moira Stephens Nicky Gilroy: Emerging Threats in Microbiology and New Antibiotic Therapies [114]</p>
1630-1730	<p style="text-align: center;">HSANZ ANZSBT ASTH BMTSAA Nurses Joint Poster session</p> <p style="text-align: center;">Session sponsored by Janssen-Cilag</p>	<p>HSANZ Masterclasses</p> <p>1 Pier Luigi Zinzani (sponsored by Amgen): Treatment of primary mediastinal large B-cell lymphoma Chair: Max Wolf (Skyline 1)</p> <p>2 Ayalew Tefferi: Controversial issues in ET/PV Chair: Kerry Taylor (Skyline 2)</p> <p>ANZSBT Masterclasses</p> <p>4 Jill Story: Challenging serological problems Chair: David Roxby (Mtg Room 5)</p> <p>5 Roger Dodd: Assessing Transfusion Risk Chair: Ken Davis (Mtg Room 2)</p>		<p>Harbourside Mtg Room 4</p> <p>NURSES Chair: Beverleigh Quested Sally Greenaway: Palliative Care and Haematology – On the Same Side! [115] James Isbister: An Evidence Based Approach to Plasma Exchange [116]</p> <p style="text-align: center;">Session sponsored by Baxter Healthcare</p>

HSANZ Concurrent Free Communication Sessions – Monday 17 October: 0830 - 1000

HSANZ Free Communications 1: Lymphoma / HD (Auditorium)

Chair: Michael Harvey

- 43 **Steven Lane:** Pegfilgrastim Compared to Granulocyte Colony Stimulating Factor (G-CSF) with Hyper-CVAD Chemotherapy Regimen for Aggressive Lymphoid Malignancy
- 44 **Heather Robinson:** HyperCVAD+Rituximab Followed by High-Dose Busulfan, Melphalan and Autologous Stem Cell Transplantation in First Response Produces Excellent Safety and Event-Free Survival in Mantle Cell Lymphoma
- 45 **Andrew Spencer:** An Outpatient Lymphoma Salvage Approach Incorporating Risk Stratification and Treatment Escalation
- 46 **David Ritchie:** Augmented Preparative Regimens Using Total Body Irradiation or BCNU Prior to Autologous Stem Cell Transplant (AuSCT) are Well-Tolerated and Yield Substantial Rates of Progression-Free Survival in Patients with Poor Risk Hodgkin Lymphoma (HL) or Diffuse Large B-Cell Lymphoma (DLBCL)
- 47 **Jake Shortt:** Adjuvant Rituximab Causes Prolonged Hypogammaglobulinaemia and Neutropenia Following Autologous Peripheral Blood Stem Cell Transplant for Non-Hodgkin's Lymphoma
- 48 **Andrew Wirth:** Risk and Response Adapted Treatment for Early Stage Hodgkin's Lymphoma (ESHL): Three Year Results of an Australian Leukaemia and Lymphoma Group/Trans-Tasman Radiation Oncology Group Study

HSANZ Free Communications 2: Myeloma Biology (Mtg Rm 2)

Chair: Bik To

- 49 **Janelle Sharkey:** Characterisation of a Novel In Vivo Murine Model of Human Multiple Myeloma
- 50 **Gough Au:** Coxsackievirus A21 as a Novel Oncolytic Purging Agent for Multiple Myeloma
- 51 **Dirk Honemann:** The Carbohydrate Antigen Lewis^y as a Target for Immunotherapy of Multiple Myeloma
- 52 **Tiffany Khong:** Azacytidine Modulates IL-6 and p16 Gene Expression and Induces Apoptosis in Human Multiple Myeloma Cell Lines
- 53 **Janelle Sharkey:** PKC412 Induces c-jun Phosphorylation Mediated Apoptosis in Human Multiple Myeloma Cell Lines
- 54 **Karly Koutrouvelis:** Bcl-xL Mediates Resistance to TRAIL-Induced Apoptosis in Multiple Myeloma

HSANZ Free Communications 3: Transplantation / Cell Therapy (Mtg Rm 5)

Chair: Jeff Szer

- 55 **Ian Nivison-Smith:** Haemopoietic Stem Cell Transplants for Chronic Myelofibrosis - A Review from the ABMTRR
- 56 **Jason Butler:** Fludarabine/Melphalan Conditioning for Allogeneic Stem Cell Transplants in Older Patients with AML/MDS
- 57 **Mingus Rose:** A Practical Approach for Assessing Donor Natural Killer Cell Alloreactivity in Haploidentical HSCT
- 58 **Anthony Schwarzer:** KIR-Ligand Mismatched Haploidentical Haematopoietic Stem Cell Transplantation (haploHSCT) for Advanced Haematological Malignancies: Alfred Hospital Experience
- 59 **Ken Micklethwaite:** Prophylactic Infusion of CMV pp65 Specific Cytotoxic Lymphocytes (CTL) Following Haemopoietic Stem Cell Transplantation (HSCT)
- 60 **Anna Hansen:** Ex-Vivo Expansion of CMV Specific CTL for Therapeutic Use in Allogeneic Haemopoietic Stem Cell Transplantation (HSCT)

HSANZ Free Communications 4: Leukaemia Biology (Skyline Room 1)

Chair: Ken Bradstock

- 61 **Deborah White:** Predictive Value of Two Assays Measuring Kinase Inhibition Induced by Imatinib in CML Patients
- 62 **Linda Bendall:** CXCL12 Synergises with Cytokines to Enhance the Proliferation of Pre-B ALL
- 63 **Dachuan Guo:** Simplified Gene Expression Profiles Identified by Microarray Suggests a Potential Diagnostic Tool in Paediatric Acute Lymphoblastic Leukaemia
- 64 **Naveed Khan:** The Wnt/ β -catenin Pathway Promotes Growth and Survival of Acute Lymphoblastic Leukaemia (ALL) Cells in Vitro
- 65 **Andy Hsu:** Assembling the Players for Evaluation of Anti-Leukaemic CTL Activity in NOD-SCID Mice
- 66 **Julius Juarez:** CXCR4 Antagonists Mobilize Acute Lymphoblastic Leukemia Cells into the Peripheral Blood and Inhibit Engraftment in Mice

ANZSBT Free Communications 1: Transfusion Practice Improvement (Harbourside Room) 1530 - 1630

Chair: Nicole Staples

- 108 **Trudi Verrall:** Best Practice in Transfusion Specimen Labelling - Declaration of Positive Patient Identification
- 109 **Nadine Gilby:** Transfusion Practice Improvement Strategies, Raising Awareness and Knowledge of Transfusion Issues in Victoria and Tasmania
- 110 **Jennifer Mitchell:** Adapt, Adopt or Augment: Strategies for Change in the Blood Service?
- 111 **Christopher Corkery:** A Retrospective Audit of Irradiated Component Use in New Zealand

Tuesday 18 October

0800-1800	Registration		Foyer – Level 2
0830-1000	<p>HSANZ Free Communications:</p> <p>5 Myeloma Therapy (Auditorium) Chair: Pauline Warburton Abs # 117– 122</p> <p>6 Lymphoma / Lymphopoiesis (Mtg Room 4) Chair: Graham Young Abs # 123 – 128</p> <p>7 Transplantation / Practical Considerations (Mtg Room 5) [0830 – 1015] Chair: Tony Dodds Abs # 129 – 135</p> <p>8 Genetics of Leukaemia & Myeloproliferative Disorders (Mtg Room 2) Chair: Bryone Kuss Abs # 136– 141</p> <p>9 Experimental Therapeutics (Skyline 1) Chair: Derek Hart Abs # 142 – 147</p>	<p>Harbourside Room</p> <p>ANZSBT Report from Scientific Subcommittee and QAP</p>	<p>Harbourside Mtg Room 3</p> <p>ASTH Free Communications 2 Laboratory Science Chairs: Joanne Joseph & Tom Exner Vanessa Cole: Genetic Confirmation of Protein S Deficiency [148] Joanne Joseph: A Combined Clinical and Laboratory Algorithm for the Diagnosis of HIT [149] David Connor: The Diagnostic Utility of Flow Cytometric Methods in Assessment of Platelet Disorders [150] Jennifer Curnow: Changes in Traditional and New Thrombophilic Markers During Treatment of Active Prostate Cancer [151] Helen Middleton: Assessment of a New Immunoturbidometric Assay of Von Willebrand Factor Activity [152] Julie Crawford: Prothrombinex Use for the Reversal of Warfarin; Is Fresh Frozen Plasma Needed? [153]</p>
1000-1030	Morning Tea Exhibition Area - Bayside Banquet Hall – Ground Floor		
1030-1200	<p>Auditorium</p> <p>HSANZ / BMTSANZ Symposium Stem Cells as a Therapeutic Modality Chair: Andrew Roberts Margaret Goodell: Haematopoietic Stem Cells for Non-Haematopoietic Disease [154] Martin Pera: Ex vivo Differentiation of Embryonal Stem Cells [155] Bob Graham: Stem Cell Therapies for Heart Disease – Past Progress, Future Challenges [156]</p>	<p>Harbourside Room</p> <p>ANZSBT Symposium The Iron Maiden Chair: Helen Savoia John Olynyk : Iron Metabolism and Assessment of Iron Stores [157] Maria Makrides: Iron Nutrition in Pregnancy and Early Life [158] Tony Keller: Iron and the Blood Donor: What Have We Learnt? [159]</p>	<p>Harbourside Mtg Room 3</p> <p>ASTH Symposium Hypercoagulability – A Lab Perspective Chair: Tom Exner Jean-Marie Freyssinet: Microparticle Determination Methodologies [160] Jenny Curnow: Global Coagulation Assays [161] Joanne Joseph: Platelet Activation [162]</p>
1200-1300	<p>PLENARY RUTH SANGER ORATION Chair: Ken Davis Robyn Barlow: Every Evening at the Bun Shop [163]</p>		Auditorium

1300-1400	Lunch AGM for ANZSBT		Exhibition Area - Bayside Banquet Hall – Ground Floor Harbourside Room
1400-1500	Auditorium HSANZ Symposium Deep Marrow Mischief Chair: John Norman Lewis Silverman (sponsored by Pharmion): 5-azacytidine in Myelodysplasia [164] Alois Gratwohl: Aplastic Anaemia [165]	Harbourside Room ANZSBT Symposium New Developments Chair: John Rowell Jill Storry: Novel Approaches for Blood Group Genotyping [166] Lars Nielsen: Toward In Vitro Production of Blood Products [167]	Harbourside Mtg Room 3 ASTH Symposium Cancer and Thrombosis Chair: Tim Brighton Agnes Lee: Treatment of Venous Thromboembolism in Cancer Patients [168] Alessandra Bianchi: Screening for Malignancy in Idiopathic VTE [169]
1500-1530	Afternoon Tea		Exhibition Area - Bayside Banquet Hall – Ground Floor
1530-1700	Auditorium HSANZ MORPHOLOGY & QAP Surender Juneja Meeting Room 2 HSANZ (for Trainees – by invitation only) Discussing Prognosis in Lymphoma Facilitators: Fran Boyle & Stewart Dunn	Harbourside Room ANZSBT Free Communications 2: Adverse Events and Governance Chair: Peta Dennington Simon Benson: The Introduction of a National Haemovigilance Programme [170] Simon Benson: The NZBS 'DHB Clinical Oversight Programme' [171] Andrew Davis: First Yield for HIV-1 NAT in the Australian Blood Donor Population - A Repeat Donor With Acute HIV-1 Infection [172] Richard Charlewood: Reducing the Risk of HBV Transmission [173] Tessa Hillgrove: Transfusion Risk Perceptions of the Australian Public [174]	Masterclasses (1530-1630) HSANZ 6 Thomas Kipps: CLL – The Clinical Impact of Translational Research Chair: David Ritchie (Skyline 1) Masterclass 6 sponsored by Pfizer 7 Margaret Goodell: Stem Cell Research: Tricks of the Trade Chair: John Rasko (Skyline 2) ANZSBT 8 Sandra Gray/Liz Pirie : Developing the Role of the Specialist Transfusion Practitioner Chair: Bev Quested (Mtg Room 4) 9 Lynn Boshkov: Does Non-leukodepleted Blood Kill? Chair: James Isbister (Mtg Room 5) ASTH 10 Agnes Lee: Challenges in Coagulation Chair: Chris Ward (Mtg Room 3)
1700-1800	HSANZ ANZSBT ASTH BMTSAA Nurses Joint Poster session		Harbourside Room North & Foyer Level 2
1900	Conference Dinner – Sponsored by Schering		Dockside, Cockle Bay Wharf

HSANZ Concurrent Free Communication Sessions – Tuesday 18 October: 0830 - 1000

HSANZ Free Communications 5: Myeloma Therapy (Auditorium)

Chair: Pauline Warburton

- 117 **Miles Prince**: The Addition of Celecoxib to Thalidomide Improves Outcome in Patients with Relapsed and Refractory Multiple Myeloma
- 118 **Miles Prince**: Increased Marrow CD57+ Cytotoxic T Cells is a Powerful Prognostic Marker for Survival in Patients with Relapsed Multiple Myeloma (MM) Receiving Thalidomide
- 119 **Tiffany Khong**: In Vitro Anti-Myelomatous Activity of the Proteasome Inhibitor Bortezomib is Highly Schedule Dependent
- 120 **Miles Prince**: Efficacy of Single-Agent Bortezomib Versus Thalidomide in Patients with Relapsed or Refractory Multiple Myeloma: A Systematic Review
- 121 **Stephanie Lee**: Health-Related Quality of Life (HRQL) Associated with Bortezomib Compared with High-Dose Dexamethasone in Relapsed Multiple Myeloma (MM): Results from APEX Study
- 122 **Melita Kenealy**: Lenalidomide (Revlimid) Achieves a High Response Rate in Patients with Relapsed or Refractory Multiple Myeloma: Local Analysis of the International MM010 & MM012 Studies

HSANZ Free Communications 6: Lymphoma / Lymphopoiesis (Meeting Room 4)

Chair: Graham Young

- 123 **Stephen Carlin**: Isolation of Common Lymphoid Progenitors from Adult Bone Marrow/Peripheral Blood CD34++ Cells With In Vitro T Lineage Differentiation Capacity
- 124 **Nina Chetty-Raju**: Populations of B Cells Lacking Surface Immunoglobulin L Chain Expression are Highly Associated with B-Lineage Lymphomas
- 125 **Shelley Rushton**: Quality Cancer Treatments - Web-based Protocols
- 126 **David Joske**: The Clinical Utility of a Lymphoma Outcomes Registry in the Management of Aggressive Lymphoma
- 127 **Michael Fulham**: The Emerging Role of PET-CT in Primary Staging of Lymphoma
- 128 **Ashley Ng**: A Mid-Treatment FDG-Positron Emission Tomography (PET) Scan is Highly Predictive of Subsequent Treatment Failure in Patients with Diffuse Large B-Cell Lymphoma (DLBCL)

HSANZ Free Communications 7: Transplantation - Practical Considerations (Mtg Rm 5)

Chair: Tony Dodds

- 129 **David Gottlieb**: Establishment of a Hospital Based Information Session for Patients, Families and Friends Prior to Stem Cell Transplantation (SCT)
- 130 **Cindy Huey-Shin Lee**: Correlation of Serum Concentrations of Cystatin C and Creatinine in Assessment of Glomerular Filtration Rate in Patients Undergoing Allogeneic Stem Cell Transplantation
- 131 **Frances Garvin**: Optimum Temperature for Maintaining the Viability of CD34+ Cells During Storage and Transport of Fresh Haematopoietic Progenitor Cells
- 132 **Peter Gambell**: Determining Acceptable Microbial Contamination Rates for PBSC Processing
- 133 **Vicki Antonenas**: Reduction in Cell Numbers Reported in Unrelated Donor Products Between Collection Facility and Transplant Hospital
- 134 **Stephen Larsen**: Mobilisation of Haemopoietic Progenitors/Stem Cells in a Non-Human Primate Model
- 135 **Divendra Hiwase**: An Evaluation of Predictive Factors for Adequate Peripheral Blood Stem Cells (PBSC) Collection

HSANZ Free Communications 8: Genetics of Leukaemia & Myeloproliferative Disorders (Meeting Room 2)

Chair: Bryone Kuss

- 136 **Lynda Campbell**: Characterisation of Dicentric 17;20 Translocations in MDS and AML: Evidence for the Retention of Critical Genes Accompanying Chromosome Deletion
- 137 **Alberto Catalano**: Breakpoint Clustering and Alternative Splicing in the Bcr2 Breakpoint Subtype of PML/RARA
- 138 **David Ross**: Peripheral Blood Quantitative PCR for BCR-ABL Can Replace Routine Bone Marrow Cytogenetics for Monitoring of Chronic Phase Chronic Myeloid Leukaemia Patients Treated with Imatinib
- 139 **William Stevenson**: Haemopoietic Cells Bearing the Jak2V617F Mutation are Present at Very Low Levels in the Peripheral Blood in Some Patients with ET
- 140 **Angela Tan**: Rapid and Sensitive Methods for the Detection of C-KIT D816V Mutations in Mastocytosis Patients
- 141 **Alberto Catalano**: Secondary Gene Rearrangements in FIP1L1/PDGFR α Positive Hypereosinophilia Syndrome

HSANZ Free Communications 9: Experimental Therapeutics (Skyline Room 1)

Chair: Derek Hart

- 142 **Silvia Ling**: A Pilot Study of the Effect of Imatinib Mesylate on Porphyrin Elimination
- 143 **Sia Hanlon**: Rapid Clinical and Molecular Response to Dasatinib (BMS 354825) in a CML Patient with Myeloid Blast Crisis and Imatinib Resistance Not Due to Kinase Domain Mutation
- 144 **Lisa Lincz**: Pathways of All-Trans-Retinoic Acid Resistance in the Acute Promyelocytic Leukaemia Cell Line NB4

- 145 **Kylie Mason**: Eliminating Tumor Cells with Small Molecule Inhibitors of Pro-Survival Bcl-2 Proteins
- 146 **David Ritchie** : In Vivo Tracking of Macrophage Activated Killer Cells to Sites of Metastatic Ovarian Carcinoma
- 147 **Lubomira Jamriska**: Development of Acute Myeloid Leukemia NOD/SCID Mouse Model to Assess CD300 Antibodies as Therapeutics for AML

Wednesday 19 Octobe 0800 – 1400 Registration		Foyer Level 2	
0830-1000	Auditorium HSANZ Free Communications 10 Transplantation/Graft vs Host Disease (Auditorium) Chair: Richard Herrmann Abs # 175 – 180 11 Lymphoma/CLL (Mtg Room 2) Chair: Leanne Berkahn Abs # 181 – 186 12 Haemopoiesis/Stem Cells (Mtg Room 4) Chair: Kathy Crosier Abs # 187 – 192 13 Myeloma/Amyloidosis (Mtg Room 5) Chair: Miles Prince Abs # 193 – 197	Harbourside Room ANZSBT Free Communications 3: Clinical Immunohaematology Chair: Richard Charlewood Marija Borosak: Neonatal Alloimmune Thrombocytopenia - A 5 Year Victorian Experience [198] Robert Flower: The Mystery of the Missing Miltenberger - What is the Basis of Non-B-A-B Mi(a)-Pos Phenotypes in Asia? [199] Jill Storry: First Example of the Para-Bombay Phenotype in an Australian Proband is Encoded by a Novel FUT1 allele [200] Julie Crawford: Alloimmunisation in the Setting of Apheresis Single Donor Platelets. A Review of Haematology Patients Undergoing Chemotherapy or Bone Marrow Transplantation [201] Christina Brown: Incidence of Red Cell Alloantibodies in Two Multitransfused Populations [202] Annette Hughes: Laboratory Investigation of Drug Induced Thrombocytopenia [203]	Harbourside Mtg Room 3 ASTH Free Communications 3 Basic and Applied Science Chairs: Scott Dunkley & Mark Smith Quintin Hughes: Regulation of the Transcription of Protein S mRNA Levels by Sex Hormones [204] Scott Dunkley: A Familial Platelet Function Disorder Associated with Abnormal Signalling Through the Glycoprotein VI Pathway [205] Fiona Scorgie: Tissue Factor Pathway Inhibitor (TFPI) Polymorphisms and Activity in Patients prone to Venous Thromboembolism (VTE) [206] Michael Ray: Increased CD 40 Ligand Expression on Platelets is Associated with Cardiovascular Events After Total Hip Arthroscopy [207] Aygul Simsek: Phenotypic Expression of Haemophilia A in Female Carriers [208]
1000-1100	Morning Tea & Announcement of Prizes		Exhibition Area - Bayside Banquet Hall – Ground Floor
1100-1200	Auditorium HSANZ ALLG Leukaemia Symposium Chair: Harry Iland Lewis Silverman (sponsored by Pharmion): Novel Therapeutic Targets in AML [210] Ayalew Tefferi: Diagnosis and Treatment of Primary Eosinophilia [211] Session sponsored by Pharmion	Harbourside Room ANZSBT Symposium Let's Think Globally Chair: Patrick Coghlan Roger Dodd: The Challenges of Providing Safe Blood in Africa [214] Miriam O'Connor: Bloody Obstetrics: A Developing Country Perspective [215] Kit Lin: China: The New Blood Service [216] Carol O'Shea: Voluntary, Non-remunerated Blood Donation – Establishing Cultural Change in Developing Countries [217]	Harbourside Mtg Room 3 ASTH Symposium New Anticoagulants Chair: Ross Baker Agnes Lee: Roles of LMWH - More Than Just an Anticoagulant [218] Tim Brighton: Anti-thrombin Inhibitors [219]
1200-1300	Auditorium HSANZ Future Directions in Lymphoproliferative Disorders Chair: Mark Hertzberg Pier Luigi Zinzani (sponsored by Amgen): Optimising Fludarabine-containing Regimens in Follicular Lymphoma [212] Thomas Kipps: Gene Therapy for CLL [213]		Harbourside Mtg Room 3 ASTH Symposium New Topics in Coagulation Chair: Chris Ward Paul Harper: Protein Z and ZPI [220] Vivien Chen: The Role of Tissue Factor [221]
1300-1400	Lunch BMTSANZ AGM		Exhibition Area - Bayside Banquet Hall – Ground Floor Harbourside Meeting Room 3

HSANZ Concurrent Free Communication Sessions – Wednesday 19 October: 0830 - 1000

HSANZ Free Communications 10: Transplantation / Graft vs Host Disease (Auditorium)

Chair: Richard Herrmann

- 175 **Lachlan Hayes:** Critical Determinants of Quality of Life (QoL) in Long-term Australian Survivors of Allogeneic Bone Marrow Transplantation (alloBMT)
- 176 **Jenny Lau:** Expression of Dendritic Cell Activation Marker, CMRF-44, on Blood CD11c+ LIN-, HLA-DR+ Dendritic Cells is Closely Associated with the Onset of Acute GVHD After Allogeneic Haematopoietic Stem Cell Transplant
- 177 **Victoria Watt:** Resting B Cells Suppress CD8+ T Cell Function and Prevent the Induction of Graft Versus Host Disease
- 178 **Brie Turner:** In vivo Dendritic Cell Depletion to Attenuate Graft Versus Host Disease in a Murine Transplant Model
- 179 **Jason Butler:** Efficacy of Soluble TNF α Inhibitor (Etanercept) for Treatment of Steroid Refractory Acute Graft versus Host Disease Post Allogeneic Stem Cell Transplantation
- 180 **Brie Turner:** The Effect of HSCT Transplant Conditioning Regimens on Murine Dendritic Cell Subsets

HSANZ Free Communications 11: Lymphoma / CLL (Meeting Room 2)

Chair: Leanne Berkahn

- 181 **Dennis Carney:** The Matutes Scoring System Remains a Valuable Diagnostic Tool
- 182 **David Westerman:** Flow-Cytometric Zap-70 Analysis in Chronic Lymphocytic Leukaemia (CLL): The Peter Mac Experience
- 183 **Alwyn D'Souza:** Pax-5 Demonstrates Residual B-Cells in Bone Marrow Trepines Post Anti-CD20 Immunotherapy
- 184 **Helen Middleton:** Accelerated Delivery of Rituximab is Safe on an Out-Patient Basis
- 185 **Mark Polizzotto:** Delivery and Toxicity of Fludarabine-Based Combination Chemotherapy Regimens in Patients Aged 60 and Older
- 186 **John Seymour:** The Risk of Myelodysplasia (MDS) and Secondary Acute Myeloid Leukemia (sAML) Among Patients Treated with Fludarabine & Cyclophosphamide (FC), FC-Rituximab (FC-R) or FC-Mitoxantrone-Rituximab (FCM-R)

HSANZ Free Communications 12: Haemopoiesis / Stem Cells (Meeting Room 4)

Chair: Kathy Crosier

- 187 **Andrew Perkins:** Zebrafish Kruppel-like Factor, KLF4, is Essential for Primitive Haematopoiesis
- 188 **Lacey Johnson:** IFI16: A Novel TPO Induced Gene Identified by Microarray
- 189 **William Stevenson:** Models of Thrombocytosis Dependent on Genetic Changes in the Thrombopoietin Pathway
- 190 **Andrew Perkins:** Specific Activation of Human but not Murine Beta-Globin Gene Expression by the Transcription Factor Ikaros
- 191 **Andrew Perkins:** Erythroid Kruppel-like Factor Regulates the Cell Cycle in Erythroid Cells
- 192 **Melissa Khoo:** Pluripotent Characteristics of Human Bone Marrow Derived Mesenchymal Stem Cells in Long Term Culture

HSANZ Free Communications 13: Myeloma / Amyloidosis (Meeting Room 5)

Chair: Miles Prince

- 193 **Ashley Ng:** CD 138 Immunostaining of Bone Marrow Trepine Specimens is the Most Sensitive Method for Quantifying Marrow Involvement in Patients with Plasma Cell Dyscrasias
- 194 **Divendra Hiwase:** Peripheral Blood Stem Cell Transplantation (PBSCT) for Multiple Myeloma Factors that Influence Engraftment
- 195 **Dominic Wall:** Tracking Dendritic Cell in-vivo in Patients with Multiple Myeloma
- 196 **Divendra Hiwase:** Successful Second Mobilization of Peripheral Blood Stem Cells Using Recombinant Human Stem Cell Factor (SCF) and Granulocyte Colony Stimulating Factor (G-CSF) in Patients with Multiple Myeloma who Failed Prior Mobilization
- 197 **Peter Mollee:** Utility of the Serum Free Light Chain Assay in Patients with AL Amyloidosis

ANZSBT Posters

- P01 Kathleen Doherty:** Refrigeration of Platelets for Prolonged Storage: Effect on Quality Parameters
- P02 Rosie Hawes:** Reducing the Risk of Bacterial Contamination in Blood Components from the New Zealand Perspective
- P03 Scott Mackenzie:** (Doherty, K.) Mode of Platelet Agitation Affects Quality of Platelets Over an Extended Storage Time
- P04 Tanya Buckerfield:** Validation of Gambro BCT Trima Accel Plasma Reduced Leuco-Depleted Platelets and Plasma Utilising Baxter T-Sol Platelet Additive Solution
- P05 Anthony M De Conno:** Four Unit Leucodepleted Buffy Coat Platelet Pools in T-Sol Utilising Terumo Tereflex BP Kit with Imugard III-S PI Filter
- P06 Casilda Cannon:** Rh D Immunoglobulin Prophylaxis in Rh D Negative Haematology Patients. Is Prophylaxis Really Required?
- P07 Margaret McNally:** Prophylactic Anti-Rh (D) Immunoglobulin - Impact on the Laboratory
- P08 Carmen Muzzolini:** Case Study: Anti-D Formation in a Parital D (DAU-4)
- P09 Greg McPhee:** Screening for Feto-Maternal Haemorrhage Using Acid Elution Techniques
- P10 Jeremy Robertson:** Foetomaternal Alloimmune Thrombocytopaenia Presenting as Severe Neonatal Hyperbilirubinaemia: A Case Report
- P11 Jonathan Blackwell:** Parallel Testing for Maternal Alloantibodies by Column Agglutination Techniques
- P12 Jonathan Blackwell:** Testing for Blood Group and Antibody Screening After 30 Days Storage of EDTA Specimen at 4 C
- P13 Julie Crawford:** Improving Detection of Drug-Induced Thrombocytopenia in the Hospital Setting Through the Introduction of a Diagnostic Algorithm
- P14 Sinha Romi:** Severe Immune Haemolysis Following Orthotopic Liver Transplantation
- P15 Richard Charlewood:** A Prospective Clinical Audit of Intravenous Immunoglobulin (IVIg) Use in New Zealand
- P16 Elizabeth Fong:** Electronic Monitoring of Transfusion Quality Assurance Throughout Western Australia
- P17 Neil Waters:** Blood Component Wastage: A Simple System for Data Collection
- P18 Russell Hunt:** Transfusion Reaction Management Project

ASTH Posters

- P19 Anne Haughton:** Quinine Induced Disseminated Intravascular Coagulation
- P20 Tim Brighton:** Low-Dose Aspirin for Secondary Prophylaxis of Vein Thrombosis - A Prospectively Planned Meta-Analysis
- P21 Raymond Hiep Banh:** Acquired Type III Von Willebrand Disease (type III AvWD): A Report on Two Cases Managed with AHF or Biostate® and a Review of the Literature
- P22 Caroline Moraes:** Using the PFA-100® to Monitor Patients on Combined Aspirin/Clopidogrel Therapy
- P23 Joanne Perel:** Experience of PFA-100® Testing in a Tertiary Level Paediatric Hospital
- P24 Joanne Perel:** Thromboelastography is Insensitive for the Diagnosis of FVIII Deficiency
- P25 Helena Hi Po Liang:** Optimization of Kinetic Assay to Measure Thrombin Generation in Platelet Rich Plasma

- P26 Roslyn Bonar:** How Useful is the Monitoring of (Low Molecular Weight) Heparin Therapy by Anit-Xa Assay? The Laboratory Perspective
- P27 Marie-Christine Morel-Kopp:** Platelet Function Measurement in Patients with Peripheral Occlusive Arterial Disease (POAD) Treated with Common Antiplatelet Regimens
- P28 Jennifer Curnow:** Thrombotic and Systemic Inflammatory Markers of Cardiovascular Risk are Lower After Eradicating Peridontitis: Results of Pericar-1 Study
- P29 Hang Quach:** Effects of Pneumatic Tube Transport System on PFA-100TM(trademark) Closure Time
- P30 Steven Lane:** Heparin Induced Thrombocytopenia and Thrombosis Syndrome Leading to Infarction and Amputation of the Right Upper Limb
- P31 David Connor:** Detergent Sclerosants Cause Cell Lysis and the in vitro Formation of Platelet-Derived Microparticles with Procoagulant Phospholipid Activity
- P32 Linda Saravanan:** An Audit of Recombinant Factor VIIa (NovoSeven) Use in Cardiac Surgery from October 2003 - June 2005
- P33 Dolly Daniel:** International Normalized Ratios Measured at Home With a Point of Care Device Diverge from Hospital Laboratory Results when Starting Warfarin

BMTSAA Posters

- P34 Jessica Stylianou:** Novel Cryoprotectant Significantly Improves the Post Thaw Quantity and Quality of HSC from Cord Blood
- P35 Rose Wong:** Correlation Between CD34(+) Stem Cells and Colony-Forming Units -GM (CFU-GM) at Time of Harvest and their Viability at Transplantation, and Haemopoietic Engraftment Kinetics After Peripheral Blood Stem Cell Transplantation
- P36 Geraldine Bollard:** Technical Factors Affecting T Cell Depletion for Haploidentical Haemopoietic Stem Cell Transplantation Using Cd34 Positive Selection with the Miltenyibiotec CliniMACS Device

Nurses Posters

- P37 Tracy Clarke:** Apheresis Procedures: Adverse Events and Outcomes
- P38 Clynt Bernhardt:** Plateletpheresis for Thrombocytosis Secondary to Chronic Myeloid Leukaemia
- P39 June Paigan:** Nursing Management of Patients Undergoing Extracorporeal Photopheresis at Peter MacCallum Cancer Centre
- P40 Yvonne Gonet:** Prevention of Intrathecal Chemotherapy Errors
- P41 Rosemary McKenna:** Transfusion Awareness Day - How to Make it Work
- P42 Zoe Grinter:** Nurse Initiated Randomised Trial on the Relief of Severe Mucositis Pain During Bone Marrow Transplant

HSANZ Posters

- P43 Diana Moore:** (Moore, D.) Experience on the Utilisation of Palifermin in Peripheral Blood Stem Cell Transplant (PBSCT)
- P44 Tara Seshadri:** Management of Autoimmune Thrombocytopenia with Rituximab: A Report of our Experience at Monash Medical Centre
- P45 Tara Seshadri:** Cryopreserved Ovarian Tissue from Patients with Hodgkin Lymphoma: Factors Predictive of Oocyte Yield and Examination for Disease Contamination
- P46 Tara Seshadri:** Effect of the "Hyper-CVAD" Chemotherapy Regimen on Female Fertility
- P47 Giuliana Scarvacì:** Improved Clinical Management of CML Patients Following Allogenic Bone Marrow Transplant Using Quantitative Real-Time PCR

- P48 Shir-Jing Ho:** Progressive Hepatic Lymphoma Successfully Treated With Regional Chemotherapy Through a Hepatic Artery Catheter
- P49 Shir-Jing Ho:** Occult Chronic Lymphocytic Leukaemia (CLL) in Patients With Aggressive Non-Hodgkin's Lymphoma: The "Reverse Richter's Syndrome"
- P50 Sarah Pett:** Preliminary Results of the Caspofungin Case Study Project: A Retrospective Study of the Clinical Experience of Cancidas® (Caspofungin acetate) for Invasive Fungal Infections in Adults in Selected Australian Hospitals
- P51 Christina Brown:** A Case of Severe Transfusion-Dependent Congenital Dyserythropoietic Anaemia Type II. Pitfalls in the Diagnosis Revisited.
- P52 Nelly Coulits:** Controlled Patient Drives - Adding Diversity to the ABMDR
- P53 Li Huimin:** Pure Red Cell Aplasia After Major ABO-Incompatible Allogenic PBSCT Treated Successfully with Plasma Exchange
- P54 Jake Shortt:** Corticosteroid-Responsive Central Nervous System Graft Versus Host Disease Complicating a Non-Myeloablative Allogenic Stem Cell Transplant for Non-Hodgkins Lymphoma
- P55 Giselle Kidson-Gerber:** Evaluation of CD34+ Selection T-cell Depletion of Bone Marrow and Peripheral Stem Cell Grafts Using the CliniMACSTM (Trademark) Device
- P56 Sharon Avery:** The Successful Treatment of Primary Cardiac Lymphoma with a Dose Dense Schedule of Rituximab-Plus-CHOP
- P57 Ni Ni Aung:** Myeloid/Natural Killer Cell Precursor Acute Leukaemia: A Case Report
- P58 Christine Hicks:** Comparison of Tc-99m MIBI (SestaMIBI) Uptake by Transformed and Multiple Myeloma (MM) Plasma Cells
- P59 Simon Zhao-Xiong He:** POEMS Syndrome - A Case Report With Poor Prognostic Features
- P60 Steven Lane:** Cutaneous Squamous Cell Carcinoma Behaves Aggressively in Patients with Chronic Lymphocytic Leukaemia
- P61 Steven Lane:** Hereditary Fibrinogen A Alpha-chain Amyloidosis
- P62 Saar Gill:** EBV-Related Haemophagocytic Lymphohistiocytosis in a Previously Well Adult: A Rare Entity Treated with Immunochemotherapy
- P63 Saar Gill:** Primary Skeletal Muscle Marginal Zone Lymphoma with Persistent Tissue Tropism and PET-Avidity
- P64 Kirk Morris:** Treatment of Adult Acute Lymphoblastic Leukaemia: The 2001-2004 Royal Brisbane and Women's Hospital (RBWH) Experience
- P65 Kirk Morris:** Successful Desensitization Protocol for Methotrexate Hypersensitivity Encountered During the Treatment of Primary CNS Lymphoma
- P66 Kirk Morris:** Isolated Central Nervous System Relapse of Acute Promyelocytic Leukaemia Confirmed by Fluorescence In-Situ Hybridisation in a 15 Year Old Male Treated with All-Trans Retinoic Acid
- P67 Jeremy Robertson:** Rituximab Use in Paediatric ITP
- P68 Alwyn D'Souza:** Zoledronic Acid Prevents Bone Loss After Allogenic Haematopoietic Stem Cell Transplantation
- P69 Alwyn D'Souza:** Morphology, Cytogenetics and Chimerism Analysis in a Case of Ph+ AML Treated with BMS-354825 Following Relapse after Reduced Intensity Allogenic Stem Cell Transplant
- P70 Heather Robinson:** Extramedullary Relapse of t(f:14), 13q Myeloma Following Autologous Stem Cell Transplant Presenting with Gastric and Skin Plasmacytomas
- P71 Heather Robinson:** PET is a Useful Tool in the Staging of Castleman's Disease

- P72 Gary Brooke:** Mesenchymal Stem Cell Isolation from Human Placenta
- P73 Sarah Barlow:** Optimisation of Rat and Mouse Mesenchymal Stem Cell Growth
- P74 Narelle Woodland:** Matrix Metalloproteinase Production by Monocytes in Pre-eclampsia
- P75 Timothy Molloy:** Gene Expression Profiling in Multiple Myeloma Cells Treated with the Novel Anti-Myeloma Agents Zoledronate and Fluvastatin
- P76 Gail Loudon:** Recurrent Malignant Melanoma Post Non-Myeloablative Stem Cell Transplant
- P77 Patricia Walker:** Hypereosinophilic Syndrome with Cardiac Involvement - A Case of Identification of FIP1L1-PDGFR α and Imatinib Response
- P78 Patricia Walker:** Corticosteroid Responsive Encephalopathy Post Allograft - A Potential Case of Hashimoto's Encephalopathy
- P79 Helen Middleton:** Paravovirus Associated Pure Red Cell Aplasia with Giant Pro-normoblasts in Two Patients Following Pancreato-Renal Transplant
- P80 Merti Hanna:** A Retrospective Cohort Study of Polycythaemia Vera in NZ Maori and Polynesian
- P81 Richard Herrmann:** Improvement in Quality of Life Correlates with Haemoglobin Improvement Following Erythropoietin Therapy in Patients with Anaemia Due to Haematological Malignancies
- P82 Amanda Johnston:** Cytomegalovirus Viraemia After Allogenic Transplant: A Prospective Study of a Risk-Adapted Strategy in a Single Transplant Unit
- P83 Helen Wordsworth:** The 8p11 Syndrome - A Case Report
- P84 Chee Wee Tan:** A Case of Gemcitabine Related Pulmonary Radiation Recall After Salvage Chemotherapy for Relapsing Hodgkin's Lymphoma Post Autologous Stem Cell Transplant
- P85 Liam Fernyhough:** Tandem High Dose Melphalan (HDM) and HLA Identical-sibling Allogenic Non Myeloablative Stem Cell Transplant (NMA-SCT) for Multiple Myeloma. A Single Centre Experience.
- P86 Xavier Badoux:** 99m_{Tc} Tc Aprotinin Scintigraphy in Amyloidosis
- P87 Chee Wee Tan:** Successful Allogenic Stem Cell Transplantation of Two Patients with Prolonged Severe Neutropenia and Invasive Fungal Infection Treated with Granulocyte Transfusions and Antifungal Therapy
- P88 Campbell Tiley:** Collaborative Establishment of New Autograft Centres by GMTT, A Clinical Network in NSW
- P89 Devendra Hiwase:** PCAB Chemotherapy Prior to Stem Cell Mobilization Adversely Affects CD34 Yield in Patients with Multiple Myeloma
- P90 Yi-Tin Chen:** A Rare Case of Primary Bone Lymphoma in Chinese Women
- P91 Yi-Tin Chen:** Acute Renal Failure Complicating Acute Promyelocytic Leukemia (APL) in Pregnancy
- P92 Simon Gibbs:** Bisphosphonate-Induced Osteonecrosis of the Jaw: A New Complication and its Implications for the Treatment of Multiple Myeloma and Other Diseases
- P93 Lynette Chee:** Hickman Line-Related Infections in Non-Neutropenic Patients with Haematological Malignancies
- P94 Wendy Osborn:** Strategy for Investigations of Patients with Red Cell Microcytosis and Hypochromia
- P95 Kenneth Romeril:** Long Term Use of Hydroxy-urea in Young Patients with Essential Thrombocythaemia and High Risk Thrombotic Risk
- P96 Mark Polizzotto:** Bisphosphonate-Associated Osteonecrosis of the Auditory Canal

- P97 Melita Kenealy:** Is Tumour Lysis Syndrome and Herpes Zoster Infection Really that Uncommon After Bortezomib?
- P98 Helen Markham:** Hydroxyurea as a Cause of Cardiac Arrhythmia and Drug Fever
- P99 Kylie Mason:** Review of Serial Bone Marrow Examination on Patients with Chronic Myeloid Leukaemia Treated with Imatinib Mesylate: Long Term Follow Up
- P100 Rajive Kumar:** What the Peripheral Blood Smear Teaches about Megakaryocytic Maturation
- P101 Oanh Nguyen:** Production and Purification of IE1-pp65. Potential CMV Antigen Source for Adoptive Immunotherapy
- P102 Kerry Atkinson:** Clinical Application of Allogenic Mesenchymal Stem Cells
- P103 Karen Viedra:** Evaluation of Transferrin Receptor/Ferritin Ratio in the Diagnosis of Iron Deficiency in Patients with Other Medical Conditions - A Pilot Study
- P104 Ranjeef Kumar:** FMC 7 Versus CD20 Expression in B Cell Lymphoproliferative Disorders - Unravelling the Relationship
- P105 Kathryn Field:** Surveillance for Healthcare-Associated Bacteraemia in an Australian Haematology-Oncology Unit
- P106 Judith Trotman:** "Rainy Day" Autologous Stem Cell Harvests in New South Wales
- P107 Li Chong:** Evaluation of Relative BCR Expression in Different Cell Lines Using DzyNA RT-PCR
- P108 Adam Bryant:** Reduced Intensity Conditioning Allogenic Stem Cell Transplantation Using Tacrolimus, Sirolimus and Methotrexate GVHD Prophylaxis in High Risk Recipients
- P109 Rebecca Howman:** An Audit of Myeloma at Fremantle Hospital
- P110 Rebecca Howman:** Cefepime Monotherapy as Empiric Treatment for Febrile Neutropaenia in Patients with Haematological Malignancies